SiBone (NASDAQ:SIBN) CFO Sells $42,702.66 in Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 3,318 shares of SiBone stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $12.87, for a total transaction of $42,702.66. Following the transaction, the chief financial officer directly owned 263,148 shares in the company, valued at $3,386,714.76. This represents a 1.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, February 17th, Anshul Maheshwari sold 21,528 shares of SiBone stock. The shares were sold at an average price of $15.37, for a total transaction of $330,885.36.

SiBone Stock Performance

Shares of SIBN remained flat at $13.12 during trading hours on Friday. 673,231 shares of the company were exchanged, compared to its average volume of 599,931. SiBone has a one year low of $12.15 and a one year high of $21.89. The stock has a market cap of $579.51 million, a P/E ratio of -29.82 and a beta of 0.77. The stock has a 50 day moving average price of $14.69 and a two-hundred day moving average price of $16.39. The company has a current ratio of 8.55, a quick ratio of 7.21 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09. SiBone had a negative net margin of 9.41% and a negative return on equity of 11.01%. The business had revenue of $56.35 million during the quarter, compared to the consensus estimate of $56.26 million. Analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SiBone

Several institutional investors have recently bought and sold shares of SIBN. ANTIPODES PARTNERS Ltd purchased a new stake in SiBone in the fourth quarter worth $29,000. Royal Bank of Canada grew its stake in shares of SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after acquiring an additional 736 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of SiBone by 64,700.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after acquiring an additional 1,941 shares during the period. State of Alaska Department of Revenue purchased a new stake in SiBone in the 3rd quarter worth about $39,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in SiBone in the 4th quarter worth about $53,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

SIBN has been the topic of a number of recent analyst reports. Truist Financial reiterated a “buy” rating and set a $24.00 price target (up from $23.00) on shares of SiBone in a report on Tuesday, February 24th. Needham & Company LLC upped their price objective on SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Canaccord Genuity Group raised their target price on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of SiBone from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, SiBone has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.